All Posts By

Smartkarma Newswire

India set to close in on China as emerging-market stock anchor

By | Press Coverage

Excerpt: Analysts from firms including Smartkarma and IIFL Securities Ltd expect India’s weight in the MSCI Emerging Markets Index to rise by at least one percentage point following the index provider’s review this week.

The Edge Malaysia • (Opens in a new window) ⧉

Are you a Professional Journalist?

The Smartkarma Press Pass is a special login created exclusively for pre-approved professional journalists. It allows a journalist to access content on the platform and use all the powerful search and discovery functionality available. Journalists can excerpt and quote from the content on Smartkarma to enrich and support their articles.


Request your Press Pass Now

India set to close in on China as emerging-market stock anchor

By | Press Coverage

Excerpt: Analysts from firms including Smartkarma and IIFL Securities Ltd. expect India’s weight in the MSCI Emerging Markets Index to rise by at least one percentage point following the index provider’s review this week.

Money Control – World • (Opens in a new window) ⧉

Are you a Professional Journalist?

The Smartkarma Press Pass is a special login created exclusively for pre-approved professional journalists. It allows a journalist to access content on the platform and use all the powerful search and discovery functionality available. Journalists can excerpt and quote from the content on Smartkarma to enrich and support their articles.


Request your Press Pass Now

India Set To Close In On China As Emerging-Market Stock Anchor Manage your data

By | Press Coverage

Excerpt: Analysts from firms including Smartkarma and IIFL Securities Ltd. expect India’s weight in the MSCI Emerging Markets Index to rise by at least one percentage point following the index provider’s review this week.

Chiranjivi Chakraborty, Abhishek Vishnoi • (Opens in a new window) ⧉

Are you a Professional Journalist?

The Smartkarma Press Pass is a special login created exclusively for pre-approved professional journalists. It allows a journalist to access content on the platform and use all the powerful search and discovery functionality available. Journalists can excerpt and quote from the content on Smartkarma to enrich and support their articles.


Request your Press Pass Now

India Set to Close In on China as Emerging-Market Stock Anchor – BNN Bloomberg

By | Press Coverage

Excerpt: Analysts from firms including Smartkarma and IIFL Securities Ltd. expect India’s weight in the MSCI Emerging Markets Index to rise by at least one percentage point following the index provider’s review this week.

bnnbloomberg.ca • (Opens in a new window) ⧉

Are you a Professional Journalist?

The Smartkarma Press Pass is a special login created exclusively for pre-approved professional journalists. It allows a journalist to access content on the platform and use all the powerful search and discovery functionality available. Journalists can excerpt and quote from the content on Smartkarma to enrich and support their articles.


Request your Press Pass Now

India set to close in on China as emerging-market stock anchor

By | Press Coverage

Excerpt: Analysts from firms including Smartkarma and IIFL Securities expect India’s weight in the MSCI Emerging Markets Index to rise by at least one percentage point following the index provider’s review this week.

Business Times SG • (Opens in a new window) ⧉

Are you a Professional Journalist?

The Smartkarma Press Pass is a special login created exclusively for pre-approved professional journalists. It allows a journalist to access content on the platform and use all the powerful search and discovery functionality available. Journalists can excerpt and quote from the content on Smartkarma to enrich and support their articles.


Request your Press Pass Now

India Set to Close In on China as Emerging-Market Stock Anchor

By | Press Coverage

Excerpt: Analysts from firms including Smartkarma and IIFL Securities Ltd. expect India’s weight in the MSCI Emerging Markets Index to rise by at least one percentage point following the index provider’s review this week.

Abhishek Vishnoi, Chiranjivi Chakraborty • (Opens in a new window) ⧉

Are you a Professional Journalist?

The Smartkarma Press Pass is a special login created exclusively for pre-approved professional journalists. It allows a journalist to access content on the platform and use all the powerful search and discovery functionality available. Journalists can excerpt and quote from the content on Smartkarma to enrich and support their articles.


Request your Press Pass Now

CAR Group (CAR) Earnings: FY Adjusted Net Income Meets Estimates at A$344.0 Million

By | Earnings Alerts
  • CAR Group’s adjusted net income for the fiscal year came in at A$344.0 million, slightly below the estimate of A$344.1 million.
  • Reported net income was A$250.0 million, underperforming the estimate of A$281.8 million.
  • Final dividend per share increased to A$0.385 from A$0.3250 year-over-year.
  • Revenue from continuing operations matched expectations at A$1.10 billion.
  • Analyst ratings include 8 buys, 6 holds, and 3 sells.

A look at CAR Group Smart Scores

FactorScoreMagnitude
Value2
Dividend2
Growth5
Resilience2
Momentum4
OVERALL SMART SCORE3.0

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, CAR Group Limited has received a solid overall outlook based on various factors. With a strong Growth score of 5, the company is positioned well for long-term expansion and development in the digital vehicle marketplace. Additionally, the Momentum score of 4 indicates that CAR Group is benefitting from positive market trends and investor interest, pointing towards a promising future ahead.

While CAR Group scores moderately on Value, Dividend, and Resilience, its high ratings in Growth and Momentum suggest a positive trajectory for the company. As an operator of a digital vehicle marketplace serving a global customer base, CAR Group is well-positioned to capitalize on emerging opportunities in the automotive industry. Investors may find potential in the company’s growth prospects and market momentum as key drivers of long-term success.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Aurobindo Pharma (ARBP) Earnings: 1Q Net Income Misses Estimates Despite Revenue Growth

By | Earnings Alerts
  • Net income: 9.19 billion rupees, up 61% year-over-year, but below the estimate of 9.41 billion rupees.
  • Revenue: 75.67 billion rupees, up 10% year-over-year, slightly below the estimate of 75.8 billion rupees.
  • Active pharmaceutical ingredients sales: 10.92 billion rupees, up 6% year-over-year, below the estimate of 11.56 billion rupees.
  • Europe sales: 19.82 billion rupees, up 7.7% year-over-year, beating the estimate of 19.01 billion rupees.
  • US revenue: 35.55 billion rupees, up 13% year-over-year, above the estimate of 34.9 billion rupees.
  • Rest of the world revenue: 7.70 billion rupees, significantly higher than the estimate of 5.24 billion rupees.
  • Total costs: 64.6 billion rupees, up 6.3% year-over-year.
  • Employee benefits expenses: 10.72 billion rupees, up 13% year-over-year, higher than the estimate of 10.37 billion rupees.
  • Finance cost: 1.11 billion rupees, up 96% year-over-year, higher than the estimate of 704.2 million rupees.
  • Other income: 2.21 billion rupees, up 91% year-over-year.
  • EBITDA: 16.2 billion rupees, up 41% year-over-year, close to the estimate of 16.17 billion rupees.
  • EBITDA margin: 21.4% compared to 16.8% year-over-year, exceeding the estimate of 18.9%.
  • R&D expenses: 3.39 billion rupees.
  • Analyst ratings: 22 buys, 4 holds, 3 sells.

A look at Aurobindo Pharma Smart Scores

FactorScoreMagnitude
Value3
Dividend3
Growth2
Resilience4
Momentum4
OVERALL SMART SCORE3.2

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Aurobindo Pharma Limited, a company known for manufacturing and marketing a wide range of generic drugs, is positioned with a mixed outlook according to Smartkarma Smart Scores. With a Value score of 3 and a Dividend score of 3, the company shows stability in terms of its financial performance and dividend distribution. However, with a Growth score of 2, the company might face challenges in expanding its operations and market share in the future. On the positive side, Aurobindo Pharma scores well in Resilience with a score of 4, indicating its ability to withstand economic uncertainties, and in Momentum with a score of 4, suggesting a strong performance trend in the market.

Overall, Aurobindo Pharma‘s future prospects seem to be steady, with a focus on maintaining value and dividends, supported by its resilient nature and positive market momentum. The company’s product range includes a variety of essential drugs such as antibiotics and anti-ulcerants, which ensures a stable foundation for its business operations. While growth opportunities may be a bit constrained, Aurobindo Pharma‘s strong resilience and market momentum are expected to keep it on a steady course in the pharmaceutical industry.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Top 10 Highlights from the APAC PE, VC and Startup Ecosystem this Week – 11 Aug 2024

By | Private Markets, Smartkarma Newswire

Top ten highlights from the APAC PE, VC, and startup ecosystem this week:

  1. Temasek Invests in GP-led Secondaries: Singapore state investor Temasek focuses on GP-led secondaries for longer asset retention.
  2. Silicon Box Secures $100M Funding: Singapore-based semiconductor startup raises funds led by Prysm Capital.
  3. Taylor’s Education Group Eyes Acquisition: Malaysian education company backed by KKR considers acquiring Vietnam-based Koala House.
  4. Macquarie Asset Management Closes South Korea PE Fund: Latest fund set to close at over 1 trillion won in Q3 of this year.

APAC Private Markets Research

Explore latest Insights on APAC Private Markets on Smartkarma


Disclaimer:This article by is general in nature and based on publicly available information and not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material. While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Also, check out the latest in ECM Research on Smartkarma